To date, a watch-and-wait strategy is generally performed in all patients with AS irrespective of disease progression rate.8,9,11 Therefore, the development of an effective prevention strategy of AS is an unmet need in modern patient care.13 Our findings imply that targeting MIF secretion and MIF-regulated processes pharmacologically may be a future treatment option to delay/prevent progression of DAVD. The gene discussed is MIF; the disease is aortic stenosis.